LECTURE NOTES on BP 703T. PHARMACY PRACTICE
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
•Prescription Review •Medication Review
THE USE OF CLINICAL PHARMACISTS AND PHARMACONOMIST SERVICES IN REGARDS TO RESOURCE CONSUMPTION AND MEDICATION SAFETY IN A DANISH HOSPITAL SETTING Laura Victoria Moesgaard Lech, stud.pharm, School of Pharmaceutical Sciences, Trine Rune Høgh Nielsen, cand.pharm, ph.d., Region Zealand Hospital Pharmacy, Lona Louring Christrup, cand.pharm. ph.d., School of Pharmaceutical Sciences. Denmark. BACKGROUND RESULTS Drug-Related Problems (DRPs) are factors for increased Over the course of three weeks, 157 patients were included. morbidity, mortality and costs in the health-care system. Preventing, Number of DRPs: In total, 515 DRPs were identified (bar chart). identifying and solving DRPs are therefore essential for the There was no significant statistic difference between the number of medication safety in hospital settings. Two approaches for this are DRPs identified by PMM and CPS (Mann-Whitney, p> 0.05). the use of clinical pharmacists (MSc in pharmaceuticals and post graduate courses) and pharmaconomists (3-year education in Type of DRPs: The most frequent problem in PMM and CPS were pharmaceuticals). “costs-effectiveness” and “treatment effectiveness”, respectively, accounting for more than half of all DRPs. The type of DRPs were AIM statistically significant between across all groups (χ2, p<0.05). To investigate the number, type and severity of DRPs identified by Pharmaconomist Medication Management (PMM) and Clinical Pharmacist Service (CPS), respectively. Severity: The distribution of the severity of the DRPs across the To assess the resource consumption per patient for the PMM and three groups are shown in the bar chart. The distribution of severity 2 the CPS, respectively. was significantly different across all groups (χ , p<0.05). -
Clinical Pharmacy Specialist
SAMPLE JOB DESCRIPTION Clinical Pharmacist Specialist I. JOB SUMMARY The Clinical Pharmacist Specialists are responsible and accountable for the provision of safe, effective, and prompt medication therapy. Through various assignments within the department, they provide support of centralized and decentralized medication-use systems as well as deliver optimal medication therapy to patients with a broad range of disease states. Clinical Pharmacist Specialists proficiently provide direct patient-centered care and integrated pharmacy operational services in a decentralized practice setting with physicians, nurses, and other hospital personnel. These clinicians are aligned with target interdisciplinary programs and specialty services to deliver medication therapy management within specialty patient care services and to ensure pharmaceutical care programs are appropriately integrated throughout the institution. In these clinical roles, Clinical Pharmacist Specialists participate in all necessary aspects of the medication-use system while providing comprehensive and individualized pharmaceutical care to the patients in their assigned areas. Pharmaceutical care services include but are not limited to assessing patient needs, incorporating age and disease specific characteristics into drug therapy and patient education, adjusting care according to patient response, and providing clinical interventions to detect, mitigate, and prevent medication adverse events. Clinical Pharmacist Specialists serve as departmental resources and liaisons to other -
Patient Safety Clinical Pharmacy Collaborative (PSPC) Guidebook
GUIDEBOOK Planning and Implementing a Successful Collaborative in a Rural Area How the Eastern Virginia Medical School (EVMS) Patient Safety and Clinical Pharmacy Services Collaborative is changing Pharmacy Services in the Eastern Virginia ACKNOWLEDGEMENTS Thank you to the many people who contributed to this document. We acknowledge the Eastern Virginia Medical School Patient Safety and Clinical Pharmacy Services Collaborative members who initiated the development of this document. Thank you to the participant organizations’ leadership members who consistently supported these efforts. The following individuals provided extensive time, effort and dedication to the development of this document: Judy Wessell Judy A. Wessell MSN, APRN, BC, ACRN, AACRN, AAHIVS. Ms. Wessell has been an HIV Nurse Practitioner for 13 years and a Registered Nurse for greater than 36 years. She received her diploma of Nursing from the Newport Hospital School of Nursing in Newport, RI, her BSN and MSN at Old Dominion University, Norfolk, VA. Ms. Wessell is currently the Nurse Practitioner Supervisor at the Eastern Virginia Medical School (EVMS), Center for Care of Immune Deficiency (C3ID), Infectious Disease Clinic. She is an HIV Health Educator with the EVMS AIDS Resource and Consultation Center, providing professional and community educational programs. She is a member of the quality improvement committee and a member of the EVMS Patient Safety and Clinical Pharmacy Collaborative. Tanya Kearney Tanya K. Kearney, MPA, has eight years of experience as Director for the AIDS Resource Center at Eastern Virginia Medical School. She works with health care providers, community- based AIDS service organizations, government agencies, professional associations and academic and community health care providers, to offer multidisciplinary educational programs on HIV/AIDS and other related topics. -
Clinical Pharmacy in Family Practice
Clinical Pharmacy in Family Practice John P. Geyman, MD One of the innovative directions in family prac services has been high.2 Similar collaborative ef tice during the last several years has been the in forts between family practice and clinical phar troduction of clinical pharmacists into some teach macy have been reported in other medical schools, ing and community practices. This is not surpris such as the Medical University of South Carolina2; ing in view of recent changes in pharmacy educa and in community hospital based family practice tion and practice, which have expanded the clini residencies, such as Family Medicine Spokane in cal training of clinical pharmacists and increased Washington State.4 the range of services which they provide. There With regard to community practices, several are growing numbers of clinical pharmacists in questions are immediately raised concerning this teaching hospitals, outpatient clinics, mental kind of interdisciplinary practice, including ethical health centers, and other institutional settings.1 and economic issues, if dispensing of drugs is to be Although the entry of clinical pharmacists into the carried out; also, logistic and procedural ques relatively smaller group settings of family practice tions; cost-benefit questions; and questions re is still an early trend, the experience to date in garding satisfaction of patients, physicians, and both teaching and community practice settings is pharmacists. Of particular interest in terms of how extremely positive. these questions have been resolved in one practice In this issue of The Journal, Love and his col is the report of Davis and his colleagues of their leagues describe the role and contributions of a experience since 1976 in a rural-suburban family clinical pharmacist in the university based family practice in Lexington, South Carolina.5 This prac practice residency program at the University of tice includes two family physicians and one clin Kentucky. -
HRSA's Patient Safety and Clinical Pharmacy Services Collaborative
HRSA’s Patient Safety and Clinical Pharmacy Services Collaborative (PSPC) Krista M. Pedley, PharmD, MS Collaborative Improvement Advisor Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA) Healthcare Systems Bureau (HSB) Office of Pharmacy Affairs (OPA) 1 What is the Collaborative? • Improve patient safety, improve health outcomes, through integration of clinical pharmacy services • Rapid improvement method – uses IHI model • Leading practices come from the field • Principle of “All Teach, All Learn” 2 How Does the PSPC Create Improvements? • 16 mon th rapid l earni ng mod el • Focused on improving health outcomes • Led by an expert faculty and national leaders • Creates community of learning • Learning Sessions and Action Periods are venues for change • Improvements are tracked and shared for mutual benefit 3 Institute of Medicine Findings on PtitSftPatient Safety and dE Errors • Medication Errors are Most Common • Injure 1.5 Million People Annually • Cost Billions Annually “…for every dollar spent on ambulatory medications, another dollar is spent to treat new health problems caused bhby the me dication. ” 4 HRSA’s Commitment • StSupport programs to provide th e b est and saf est care in the Nation • Take previously supported Collaboratives with documented improvements to the next level • Going beyond one disease at a time to full patient-centered care 5 Patient Safety and Clinical Pharmacy Services Collaborative (PSPC): Aim “Committed to saving and enhancing thousands of lives a year by achieving optimal health outcomes and eliminating adverse drug events through increased clinical pharmacy services for the patients we serve.” 6 PSPC Performance Goals 1. All T eams will h ave a CPS process. -
ASHP Statement on Pharmaceutical Care
Medication Therapy and Patient Care: Organization and Delivery of Services–Statements 331 ASHP Statement on Pharmaceutical Care The purpose of this statement is to assist pharmacists in under- Care. Central to the concept of care is caring, a personal standing pharmaceutical care. Such understanding must pre- concern for the well-being of another person. Overall cede efforts to implement pharmaceutical care, which ASHP patient care consists of integrated domains of care including believes merit the highest priority in all practice settings. (among others) medical care, nursing care, and pharmaceu- Possibly the earliest published use of the term pharma- tical care. Health professionals in each of these disciplines ceutical care was by Brodie in the context of thoughts about possess unique expertise and must cooperate in the patient’s drug use control and medication-related services.1,2 It is a overall care. At times, they share in the execution of the various term that has been widely used and a concept about which types of care (including pharmaceutical care). To pharma- much has been written and discussed in the pharmacy pro- ceutical care, however, the pharmacist contributes unique fession, especially since the publication of a paper by Hepler knowledge and skills to ensure optimal outcomes from the and Strand in 1990.3–5 ASHP has formally endorsed the con- use of medications. cept.6 With varying terminology and nuances, the concept At the heart of any type of patient care, there exists a has also been acknowledged by other national pharmacy or- one-to-one relationship between a caregiver and a patient. -
About Skaggs School of Pharmacy & Pharmaceutical Sciences
SOP-3363 Skaggs SOP Printed Brochure 8.5"w x 11"h 4/4 CMYK jk Content __________ Design __________ Mktg __________ Skaggs School of Pharmacy and Pharmaceutical Sciences Where Discoveries Are DeliveredSM pharmacy.ucsd.edu SOP-3363 Skaggs SOP Printed Brochure 8.5"w x 11"h 4/4 CMYK jk Content __________ Design __________ Mktg __________ About Skaggs School of Pharmacy and Pharmaceutical Sciences Offering renowned health sciences professional education, innovative clinical practice and extensive research opportunities. Our students have an average on-time graduation rate Leadership of more than 98 percent for the four-year PharmD program and an average of 99 percent NAPLEX pass > Dean, Skaggs School of Pharmacy James McKerrow, MD, PhD rates for first time exam-takers over the last five years. We also rank among leading pharmacy schools in our > Associate Dean for Admissions and Outreach research endeavors and grant funding. Rabia Atayee, PharmD, BCPS > Associate Dean for Assessment and Accreditation Collaborations Across Campus Kelly Lee, PharmD, MAS, BCPP and Around the Region > Associate Dean for Business Administration and Fiscal Affairs > School of Medicine Andrina Marshall, MA/MBA > Department of Chemistry & Biochemistry and > Associate Dean for Experiential Education Division of Biological Sciences James Colbert, PharmD > > Department of Computer Science and Engineering Associate Dean for Pharmacy Education Brookie Best, PharmD, MAS > UC San Diego Health > Associate Dean for Professional Practice Charles Daniels, BS Pharm, PhD > La Jolla -
Successful Implementation of Pharmaceutical Care in Daily Practice
Successful implementation of Pharmaceutical care in daily practice Charlotte Rossing, MSc pharm, PhD Director of Research and Professional Development Pharmakon, Danish College of Pharmacy Practice Vice-chair FIP SIG Pharmacy Practice Research @CharRossing @Charlotte Rossing © Pharmakon Pharmaceutical care Hepler & Strand 1990 1995 2000 2005 2010 2015 FIP community pharmacy section CPD Implemen- Pharmaceutical care for tation PCNE-funded the elderly Topics Pharmaceutical Care Self-management Patient satisfaction/health Academy Network Europe Good pharmacy practice Health economics master class FIP Tokyo 1993 (research) Patient effects Designing interventions “Pharmaceutical Guidelines and manuals Barriers and facilitators care in From evidence to practice Individualised interventions community Change management Implementation of new practice practice” PCNE working implementations Change management conferences Remuneration for Indicators to measure progress Every second year community pharmacy Theory and practice services Building capacity for change © Pharmakon © Pharmakon 1 Compliance Medication review technologies Clinical pharmacy Safe and effective use of in residential Counselling Dose dispensing medicines facilities at the 2004 pharmacy 2015 - and homecare Self- PCNE Municipality PCNE management Better use of Asthma TOM pharmacy OMA project medicines in project nursing homes collaboration 1990 1995 2000 2005 2010 2015 © Pharmakon Compliance Medication review technologies Clinical pharmacy Safe and effective use of in residential -
QA Coordinator in a Biotech Company Focused on the Discovery, Design and Development of Innovative Peptide-Based Medicines
Join us for a better future Be the new QA Coordinator in a biotech company focused on the discovery, design and development of innovative peptide-based medicines Zealand Pharma A/S (Zealand) aims to become a fully integrated biotechnology company leading in delivery of specialty medicines. We are passionate about improving the quality of life for patients with metabolic and gastrointestinal diseases, and other specialty or rare disease areas with significant unmet medical needs. In the QA team, we are now looking for a new colleague to help us build and maintain the structure in our quality system and to secure follow-up activities. The position will report to VP Quality. Ensure tracking and timely follow-up on quality related documentation hereunder deviations, change controls, audits and batch related documentation Maintain and track updates to Zealand’s Quality Management System Become superuser of the Quality Module in our validated electronic system, covering change management, deviation and CAPA management and audit & vendor management Become the QA superuser of Zealand’s EDMS system Ensure routine KPI reporting to management on training, SOP finalization, and relevant Quality topics Be an active part of records management and data governance in QA Assist in the planning and follow-up of the quality audit program Managing the Quality Management Review – drive the process, compile data and prepare for routine QMR including documentation and follow-up Prepare relevant batch related documentation in connection with release. Job Profile The successful candidate will be: Pragmatic and yet with a compliant quality mindset Have high standards for ethics and integrity High degree of structural skills and ability to transform them to practical solutions Strong communication skills verbally as well as in writing Energy and drive for team results, consistent high-performer Ability to work effectively in a fast-paced environment Enjoy being in a great team and achieve things together Fluent in English (company language) and Danish. -
Implementation of Clinical Services at Various Institutions
OBJECTIVES Implementation of • Describe various hospital pharmacy Clinical Services at quality improvement initiatives • List components of the framework Various Institutions necessary for expanding clinical services • Describe methods of utilizing pharmacist- Niki Carver, Pharm.D., UAMS Medical Center extenders in providing clinical services Shannon Hays, Pharm.D., White Co Medical • Discuss the development and Melanie Claborn, Pharm.D., Veterans implementation of clinical pharmacy Healthcare System of the Ozarks/UAMS NW services in primary care at a federal facility Disclosure This presenter has no conflicts of interest to Increasing Possibilities for Health- disclose. Systems Pharmacists Involvement Niki Carver, Pharm.D. Assistant Director for Medication Safety University of Arkansas for Medical Sciences 4 Objectives Definitions • Describe various hospital pharmacy ASHP – American Society of Health-System quality improvement initiatives Pharmacists CMS – Center of Medicare & Medicaid Services 1 Health-Systems Pharmacists’ ASHP 2015 INITIATIVE Possibilities • This Initiative is a program to help make medication use in health systems more effective, Readmissions scientific, and safe. There are six key goals and 31 specific objectives to be accomplished by the year 2015. NPSG, Core • The 2015 Initiative is a tool to help health- Measures system pharmacy practitioners achieve the ideals identified in the vision statement. Pharmacokinetic Dosing, • ASHP dedicates itself to achieving a vision for Therapeutic Drug Monitoring, pharmacy practice -
Pharmaceutical Interventions on Prescription Problems in a Danish Pharmacy Setting
Int J Clin Pharm DOI 10.1007/s11096-011-9580-4 RESEARCH ARTICLE Pharmaceutical interventions on prescription problems in a Danish pharmacy setting Anton Pottega˚rd • Jesper Hallas • Jens Søndergaard Received: 29 June 2011 / Accepted: 29 October 2011 Ó Springer Science+Business Media B.V. 2011 Abstract Background International studies regarding (9.4–11.1) interventions per 1,000 prescriptions. Conclusion pharmacists’ interventions towards prescription problems We found an intervention rate substantially higher than produce highly variable results. The only peer-reviewed study reported in previous Danish studies. in a Danish setting estimated an intervention rate of 2.3 per 1,000 prescriptions. With the introduction of a new tool for Keywords Clinical pharmacy Á Denmark Á Pharmacy registration, we hypothesized that a better estimate could be practice Á Primary care Á Problem prescriptions Á obtained. Objective We aimed to produce an up-to-date Pharmacists’ interventions estimate of the extent and type of pharmacists’ interventions towards prescription problems in a Danish pharmacy setting Setting The study was conducted at Copenhagen Sønderbro Impact of findings on practice Pharmacy, a large urban 24-hour pharmacy. Method Data were collected prospectively through an electronic form. All • The number of interventions on prescriptions in Danish interventions were primarily classified as either clinical or community pharmacies, is probably significantly higher administrative in nature, and further classified in a number of than older studies indicated. pre-determined subcategories. Furthermore, information • One third of the interventions in Danish pharmacies are about age, sex, time of day, the wording of the prescription, have a clinical background. the performed intervention, the person performing the inter- • Community pharmacists in Denmark intervene mostly vention and the type of prescriber were recorded. -
Clinical Pharmacist Fellowship in Drug Information
CLINICAL PHARMACIST FELLOWSHIP IN DRUG INFORMATION 2021–2023 PROGRAM BROCHURE PURPOSE The two-year post-doctoral Clinical Pharmacist Fellowship in Drug On behalf of Belmont University College of Information is designed to provide fellows with an intensive program focused in drug information, evidence-based practice, toxicology, Pharmacy and Aegis Sciences Corporation, teaching and research. It is the goal of the program to equip fellows we would like to thank prospective fellows for to serve as clinical pharmacists in a toxicology setting, university or their interest in our program. college faculty, drug information specialists, medical science liaisons or medical writers. Christy Houston Foundation Drug Information Center OBJECTIVES AND RESPONSIBILITIES BELMONT AEGIS Belmont University consists of approximately 8,400 students from Founded in 1990, Aegis Sciences Corporation is a laboratory sciences across the United States and abroad. Committed to being a leader among company specializing in healthcare services that provide science-driven teaching universities, Belmont brings together the best of liberal arts testing and consulting for clients, such as professional and amateur sports and professional education in a Christian community of learning and organizations, leading college and university athletic programs, healthcare service. The purpose of the academic portion of the fellowship program professionals, Fortune 500 companies, and government agencies is to provide fellows with exposure to academia as well as the functions throughout the United States. The Aegis experiences will be designed and responsibilities of an academic-based drug information practice. and structured to fully integrate the fellows into the daily functions and The academia experience includes providing didactic and experiential responsibilities of the Clinical Pharmacist team.